Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HyperChrono
2023-506663-33-00Phase 2Authorised
- Sponsor
- Strasbourg University Hospital
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of melatonin in hypersomnolence disorder (2 arms), sponsored by Strasbourg University Hospital. Primary endpoint: Idiopathic Hypersomnia Severity Scale (IHSS) change at 6 weeks. Planned start Dec 2023; status: authorised.
02
Drugs
melatonin
03
Conditions
hypersomnolence disorder
Beyond the preview
Go deeper on 2023-506663-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506663-33-00.